DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Information source: Walter Reed Army Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Walter Reed Army Medical Center

Official(s) and/or principal investigator(s):
KRAIG S. BOWER, MD, Principal Investigator, Affiliation: Walter Reed Army Medical Center


The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0. 15% (Alphagan P) on pupil diameter under different luminance conditions.

Clinical Details

Study design: Time Perspective: Longitudinal


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Adult active duty personnel between 18 and 50 years of age with best corrected visual

acuity of 20/20 or better. Exclusion Criteria:

- Patients not meeting above stated age criteria

- Females that are pregnant or lactating (non pregnant females of childbearing

potential will have pregnancy test prior to participating in study)

- History of serious ocular, neurological, cardiovascular disease

- History of severe systemic disease

- History of arrhythmias or high blood pressure

- Patients currently taking any type of ocular or systemic medications except


- Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil


Locations and Contacts

Walter Reed Army Medical Center, Washington, District of Columbia 20307, United States
Additional Information

Last updated: December 19, 2006

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017